# Carnegie

#### **COMMISSIONED RESEARCH**

**COMPANY UPDATE** 

07 March 2025 Sweden Capital Goods Research analysts: Hugo Lisjö Elsa Brismar

## MilDef Group

Share price: SEK229.0

Fair value range: SEK 195.0-240.0

## Completed acquisition and raised fair value range

## A strategically timed acquisition of a German defence company

On 6 March, MilDef announced the completion of its acquisition of the German company Roda Computer, which has been consolidated into MilDef since I March. As part of the payment, MilDef issued I.4 million shares in an issue of kind. We view the timing of this acquisition as good, especially given Germany's announcement to significantly increase its defence spending.

## We expect sales and EBITA contribution of SEK981m and SEK160m in 2025e

Previously, we had included Roda in our estimates from I April, but we have now adjusted this to reflect its inclusion from March. The increase in the number of shares has a negative impact on earnings per share (EPS). Our updated estimates indicate that Roda will contribute SEK981m in sales and SEK160m in EBITA in 2025e. Given Roda's historically lean operating expenses, we expect a positive EBITA margin impact for MilDef following the integration.

## EBIT growth stands out relative to similar valued companies

We have benchmarked MilDef against other defence companies in the Nordics and Europe, as well as companies listed in the OMXS All-Share index. When comparing MilDef to the broader group, we have focused on companies with similar valuations and compared their estimated financial performance for 2026e. Our conclusion is that MilDef, alongside other defence companies, is expected to show stronger growth in both sales and EBIT, which compensates for the lower EBIT margin.

## Raised our fair value range to SEK195-240 per share

Although we have not received additional information on Roda's financials, we have raised our fair value range for MilDef. This decision is driven by the positive outlook following the recent election in Germany, where the new party is more favourable towards the defence sector, as well as broader European consensus on increasing defence spending. Our new fair value range corresponds to an EV/EBITA multiple of 18.2–22.2x for 2026e, compared to European peers trading at median 18.4x and average 21.7x.

Changes in this report											
From To											
EPS adj. 2025e	6.1	6.1	+1%								
EPS adj. 2026e	8.3	8.1	-2%								
EPS adj. 2027e	10.0	9.8	-3%								

Upcoming events

Q1 Report: 29 Apr 2025 AGM 2025: 22 May 2025

Q2 Report: 18 Jul 2025

Key facts	
No. shares (m)	46.9
Market cap. (USDm)	1,059
Market cap. (SEKm)	10,751
Net IB Debt. (SEKm)	528
Adjustments (SEKm)	0
EV (2025e) (SEKm)	11,279
Free float	74.5%
Avg. daily vol. ('000)	569
Risk	High Risk
Fiscal year end	December
Share price as of (CET)	06 Mar 2025 00:00

Key figures (SEK)	2024	2025e	2026e	2027e
Sales (m)	1,201	2,578	3,234	3,670
EBITDA (m)	143	429	569	677
EBIT (m)	-209	335	461	559
EPS	-5.16	4.90	6.78	8.36
EPS adj.	1.27	6.14	8.14	9.76
DPS	0.50	0.50	1.00	1.35
Sales growth Y/Y	4%	115%	25%	13%
EPS adj. growth Y/Y	-44%	385%	33%	20%
EBIT margin	-17.4%	13.0%	14.3%	15.2%
P/E adj.	>100	37.3	28.1	23.5
EV/EBIT	neg.	33.6	24.2	19.3
EV/EBITA	53.4	29.0	21.3	17.2
EV/EBITDA	37.4	26.3	19.6	15.9
P/BV	9.5	8.2	6.8	5.6
Dividend yield	0.2%	0.2%	0.4%	0.6%
FCF yield	1.4%	-0.1%	1.2%	4.1%
Equity/Total Assets	65.4%	53.9%	57.7%	63.1%
ROCE	-16.3%	22.2%	25.0%	27.2%
ROE adj.	5.6%	23.6%	26.5%	26.3%
Net IB debt/EBITDA	-2.3	1.2	0.7	0.0



Source: Carnegie Research, FactSet, Millistream & company data

This report has been commissioned and sponsored by MilDef Group. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas. For more information, see disclosures and disclaimers at the end of this report



## **Equity story**

## Near term: 6-12m

Since the fall of the Berlin Wall, European military spending has declined, but the war in Europe has spurred a significant increase in defence budgets. As a late-cycle business, MilDef benefits from the maturing ramp-up, especially with the focus on modernisation and digitalisation, boosting demand for IT systems. The acquisition of Roda strengthens MilDef's position in Germany, providing access to government frameworks and helping replicate its successful Nordics market strategy.

## Long term: 5Y+

Technology has always been a key driver in the defence sector, and this is unlikely to change. Emerging themes include unmanned vehicles (UVs), digitalisation of military fleets, artificial intelligence (AI), soldier-assisting robots, dismounted soldier systems, space capabilities, and high-precision missiles. These trends suggest that future battlefields will rely heavily on a wide range of electrical devices, and that tomorrow's battlefield will include even more computers than today's. We see these trends as supportive for MilDef 's continued growth.

#### Key risks:

- The defence industry is built on trust, handling highly sensitive information related to national security. Maintaining rigorous compliance standards is crucial for companies, ensuring all documentation is meticulously organised. A small misstep can have severe consequences, potentially jeopardising future business opportunities.
- Increased exposure to Taiwan, the acquisition of Roda increases MilDef's exposure to Crete, a Taiwan-based company.
- Roda integration risks

## **Company description**

MilDef is a supplier of rugged IT systems, designed and built to withstand harsh environments, primarily for military use. The company mainly sells to its home market in the Nordics, Europe and the US. Over the past five years, particularly in Sweden, MilDef has demonstrated its ability to evolve from a product supplier to a systems integrator, marking a significant step up the value chain. Since IT systems are not a short-term priority in the defence sector's ramp-up, the impact of sharply increased defence budgets did not hit MilDef until 2024. As a result, we expect the company to continue demonstrating strong growth in the coming years.

### **Key industry drivers**

- Increased modernisation and digitalisation
- Increased defence spending
- Nearshoring

#### Industry outlook

## • We find it likely that defence budgets will remain high

- US is urging Europe to increase its defence investments
- We consider Europe the most interesting region in the coming years

#### Largest shareholders

•	
Svolder	9.5%
MilDef Crete	6.4%
Andra AP-fonden	5.8%

## Cyclicality

## Key peers

Cyclicality: N/A

Swedish and European defence companies like Kongsberg Gruppen, Saab, W5 Solutions, INVISIO, BAE Systems, Leonardo, Rheinmetall, and US Curtiss Wright.


## Valuation and methodology


We evaluate MilDef through a scenario analysis based on a multiples approach, comparing MilDef to defence industry peers. We examine three scenarios: a base scenario aligned with our forecasts, a low-growth scenario, and a scenario where MilDef successfully demonstrates better sales and cost synergies with Roda than our starting scenario. Our peer group consists of both Swedish and international defence companies, where we put a particular focus on European peers. Given MilDef's progression from a product supplier to more of a systems supplier, we find it reasonable to compare the company with larger companies that offer broader product portfolios within the peer group.


#### Fair value range 12m



The upper end of our fair value range is based on MilDef achieving a premium valuation relative to the peer group's median multiple. The lower end of our fair value range reflects multiple in line with peer group median EV/EBITA(26e) multiple. Since we expect MilDef to show among the best financial performances compared to the peer group, we believe it should be valued in line with or at a premium to its peers.







Source: Carnegie Research & company data



## Estimate changes due to earlier consolidation


We make only minor adjustments to estimates due to Roda being consolidated one month earlier than we previously estimated. This results in a slight positive impact on sales for 2025e and a small negative effect on gross margin. Apart from this, there are no other significant changes worth mentioning.

MilDef		New			Old			Changes	
P&L (SEKm)	2024	2025e	2026e	2024	2025e	2026e	2024	2025e	2026e
Net sales	1,201	2,578	3,234	1,201	2,480	3,232	0%	4%	0%
Growth Y/Y	4%	115%	25%	4%	107%	30%	0.0ppt	8.2ppt	-4.9ppt
Organic Y/Y	4%	33%	17%	4%	33%	17%	0.0ppt	0.0ppt	0.0ppt
Acquired Y/Y	0%	82%	9%	0%	73%	14%	0.0ppt	8.2ppt	-4.9ppt
COGS	-612	-1,497	-1,900	-612	-1,428	-1,914	0%	5%	-1%
Gross profit	589	1,081	1,333	589	1,052	1,318	0%	3%	Ι%
Gross margin	49.0%	41.9%	41.2%	49.0%	42.4%	40.8%	0.0ppt	-0.5ppt	0.5ppt
OPEX	-469	-746	-872	-469	-730	-861	0%	2%	1%
Selling expenses	-279	-462	-537	-279	-452	-525	0%	2%	2%
Admin expenses	-106	-167	-187	-106	-163	-198	0%	3%	-5%
R&D	-84	-117	-148	-84	-116	-139	0%	1%	7%
Other income/expenses	-329	0	0	-329	0	0	0%	-	-
EO	-36	-6	-2	-36	-6	-2	0%	0%	0%
Adj. EBITDA	179	435	57 I	179	419	566	0%	4%	1%
Adj. EBITDA margin	14.9%	16.9%	17.7%	14.9%	16.9%	17.5%	0.0ppt	0.0ppt	0.1ppt
Depreciation	-29	-41	-45	-29	-40	-45	0%	1%	-1%
EBITA - CAR definition	100	388	524	100	373	519	0%	4%	1%
EBITA margin - CAR definition	8.4%	15.1%	16.2%	8.4%	15.0%	16.1%	0.0ppt	0.0ppt	0.1ppt
Adj. EBITA - CAR definition	136	394	526	136	379	521	0%	4%	1%
Adj. EBITA margin - CAR definiti	11.3%	15.3%	16.3%	11.3%	15.3%	16.1%	0.0թթt	0.0ppt	0.1ppt
Amortisation & impairments - PPA	-309	-53	-62	-309	-51	-62	0%	3%	0%
EBIT	-209	335	46 I	-209	322	457	0%	4%	1%
EBIT margin	-17.4%	13.0%	14.3%	-17.4%	13.0%	14.1%	0.0ppt	0.0ppt	0.1ppt
Adj. EBIT	112	341	463	112	328	459	0%	4%	1%
Adj. EBIT margin	9.3%	13.2%	14.3%	9.3%	13.2%	14.2%	0.0ppt	0.0ppt	0.1ppt
Net financials	-14	-29	-31	-14	-24	-31	0%	18%	-1%
PTP	-223	307	430	-223	297	426	0%	3%	1%
Tax	2	-80	-112	2	-76	-111	0%	5%	1%
Net profit	-220	227	318	-220	221	315	0%	2%	1%
EPS	-5.2	4.9	6.8	-5.2	4.9	6.9	0%	1%	-2%
Adj. EPS	1.3	6.1	8.1	1.3	6.1	8.3	0%	1%	-2%

Source: Carnegie Research

## Estimates and expectations for Roda for 2025e

We acknowledge some risk in our estimates due to the lack of financial data for 2024. As a result, our forecasts for Roda are based on the announced sales and EBITA figures for 2023. When the acquisition was announced, MilDef stated that Roda achieved sales of approximately SEK800m in 2023 and an EBITA margin of 16%. Given the current market environment, we expect Roda to achieve sales growth of around 20% in 2024e, with growth of 15–17% in the following years, along with a margin expansion of approximately 1%-point.






## Benchmarking against defence peers and broader market

Before assessing our valuation and the various scenarios tied to Roda's size, it is important to consider MilDef's valuation relative to both its defence peers and the broader market. To do this, we have benchmarked MilDef against companies of similar or higher valuation listed on the OMXS All-Share index. Our new fair value range is based on an EV/EBITA multiple of 18.2–22.2x for 2026e.

### Benchmarking against defence peers

Starting with benchmarking MilDef against Nordic and European defence peers, we expect MilDef to show the second-highest sales growth. Even adjusting for the roughly 9% from acquisitions, MilDef would still be in the upper half. Given the recent EU announcements, we believe our 17% organic sales growth estimate for 2026e is reasonable.

In terms of EBITA margin, we expect MilDef to rank among the highest within its European defence peer group. Several factors support this margin improvement over the next few years. As noted earlier, Roda had an EBITA margin of 16% in 2023, which should remain positive unless there is an unforeseen decline. Historically, MilDef has shown strong margin improvements in quarters with sales increases, and while the marginal effect may be less significant in the future, we still expect higher sales volumes to drive margin growth. Additionally, the shutdown of MilDef's civil business at the end of 2024 is communicated to have a positive effect of SEK20m EBIT once the full effect is realised. Furthermore, we expect increased production volumes at MilDef's Cardiff facility and potentially higher gross margins due to stronger supplier negotiations following the acquisition.






Source: Carnegie Research, Factset

Source: Carnegie Research, Factset

In all, we expect MilDef to be a top performer compared to its European defence peers. While there are always risks in estimates, we believe MilDef is very well positioned to benefit from Germany's increased defence spending, thanks to the acquisition of Roda. As such, we do not view this risk as significantly higher than that of the rest of the peer group. Therefore, we consider it reasonable to value MilDef at a premium to its defence peers. Our new fair value range corresponds to an EV/EBITA multiple of 18.2–22.2x for 2026e, compared to European peers trading at a median of 18.4x and an average of 21.7x.









Source: Carnegie Research, Factset

## Benchmarking against the broader equity market

Compared to other defence companies, we find it reasonable to assess MilDef at a premium to its peers. However, the key question, in our view, is whether all defence companies are overvalued. To address this, we have compared MilDef's estimated financial performance against companies listed on the OMXS All-Share with an EV/EBIT(26e) valuation between 20–60x, i.e. similar to or higher than MilDef. Although we had to switch to EV/EBIT for the screening, we believe this change does not materially affect the analysis, as the difference between EV/EBITA and EV/EBIT is negligible in this context.

Our screening identified 33 companies matching this valuation range, with an average EV/EBIT(26e) valuation of 26.5x, compared to MilDef's 24.2x. A comparison of financial performance shows that MilDef is expected to demonstrate higher sales and EBIT growth, though with a lower margin, based on our estimates. The higher EBIT growth relative to sales also suggests that greater margin expansion is expected for MilDef than for the other companies in this group.





Source: Carnegie Research, Factset

To make the comparison with the broader peer group relevant, we must first consider the types of companies we are comparing MilDef against. In general, the peer group can be divided into four categories: high-quality industrial companies, tech companies, healthcare companies, and



acquirers. At a high level, these companies typically have businesses with higher scalability than MilDef. However, we believe that the structural, underlying growth within the defence sector, especially with all European countries collectively committing to increased defence investments, compensates for MilDef's relatively lower scalability at this time.

SEKm	М-сар	Sector	Sales growth 2026e	⊞ITmargin 2026e	EBIT growth 2026e	EV/EBIT2026
Yubico AB	19,410	Distribution Services	23%	23%	30%	22.5x
Xvivo Perfusion AB	12,915	Health Technology	32%	23%	68%	38.7x
Vitrolife AB	23,098	Health Technology	9%	25%	16%	22.7x
Vitec Software Group AB Class B	23,021	Technology Services	7%	23%	12%	25.4x
Truecaller AB Class B	26,376	Technology Services	28%	41%	39%	20.3x
Tobii AB	432	<b>Electronic Technology</b>	8%	2%	-	41.7x
Scandic Hotels Group AB	17,908	Consumer Services	4%	8%	10%	32.3x
Sectra AB Class B	44,379	Technology Services	15%	22%	27%	45.4x
Saab AB Class B	201,176	<b>Electronic Technology</b>	15%	10%	23%	23.0x
Precise Biometrics AB	249	<b>Bectronic Technology</b>	26%	6%	-	29.6x
OEM International AB Class B	19,604	Distribution Services	9%	15%	12%	21.0x
Nanologica AB	151	Health Technology	111%	3%	-	28.1x
Momentum Group AB Class B	8,363	Distribution Services	4%	10%	9%	27.0x
Mips AB	11,868	Consumer Durables	30%	48%	44%	26.8x
Medicover AB Class B	30,854	Health Services	13%	7%	28%	23.0x
Lime Technologies AB	5,074	Technology Services	14%	22%	19%	26.6x
Lifco AB Class B	168,605	Producer Manufacturing	8%	20%	10%	29.2x
Lagercrantz Group AB Class B	43,958	Electronic Technology	6%	16%	8%	26.5x
INVISIO AB	19,490	Electronic Technology	17%	27%	25%	31.6x
Indutrade AB	110,317	Producer Manufacturing	6%	15%	11%	21.8x
HMS Networks AB	23,683	Technology Services	17%	25%	26%	24.1x
Fortnox AB	40,151	Technology Services	23%	46%	27%	27.8x
Fingerprint Cards AB Class B	199	Electronic Technology	6%	1%	-	44.2x
engcon AB Class B	15,422	Producer Manufacturing	26%	22%	35%	25.3x
Carasent AB	1,584	Technology Services	15%	13%	199%	25.5x
BONESUPPORTHOLDING AB	22,050	Health Technology	35%	33%	73%	37.5x
BioArctic AB Class B	18,986	Health Technology	-14%	47%	-32%	24.8x
Bergman & Beving AB Class B	8,291	Consumer Durables	4%	9%	7%	20.1x
Beijer Ref AB Class B	81,562	Distribution Services	7%	11%	9%	20.1x
Bactiguard Holding AB	1,237	Health Technology	12%	11%	-	44.0x
Atlas Copco AB Class A	892,054	Producer Manufacturing	6%	23%	9%	20.5x
AddLife AB Class B	19,084	Health Services	6%	8%	14%	25.0x
Addtech AB Class B	84,079	目ectronic Technology	6%	13%	9%	27.3x
Average	60,474		16.3%	19.0%	27.4%	28.2x
Median	19,490		11.8%	16.3%	17.6%	26.5x
MILDef CARest.	10,751		25.4%	14.1%	36.0%	24.5x

Source: Carnegie Research, Factset



Defence peer group financials and valuation

	Mcap.		Sales	growth			Adj. EBIT	DA margin			Adj. EBIT	A margin			Adj. EBI	T margin			Net deb	t/EBITDA	
	(EURm)	2024	2025e	2026e	2027e	2024	2025e	2026e	2027e	2024	2025e	2026e	2027e	2024	2025e	2026e	2027e	2024	2025e	2026e	2027e
Nordic defence companies																					
KebNi AB Class B*	35	99.2%	21.6%	23.2%	21.4%	7.9%	11.6%	12.7%	15.6%	6.7%	7.6%	9.0%	12.3%	5.5%	7.6%	9.0%	12.3%	-1.7x	-0.8x	-0.8x	0.1×
Clavister Holding AB	91	19.5%	17.7%	12.4%	12.6%	16.1%	23.0%	27.6%	31.5%	-6.2%	2.1%	9.4%	15.3%	-3.6%	2.2%	9.4%	15.4%	7.9x	1.4x	l.lx	0.7×
4C Group AB	53	3.3%	13.7%	11.0%	9.7%	10.8%	21.8%	24.2%	25.3%	-1.7%	9.5%	12.0%	13.3%	-1.7%	9.5%	12.0%	13.3%	1.5×	0.0x	-0.1x	-0.3x
W5 Solutions AB*	126	1.0%	16.5%	15.1%	12.9%	7.3%	7.7%	11.2%	13.9%	-5.3%	0.2%	4.6%	8.0%	-5.3%	0.2%	4.6%	8.0%	2.6x	1.2x	0.4x	0.1×
MilDef Group AB*	943	4.3%	114.7%	25.4%	13.5%	11.9%	16.6%	17.4%	18.4%	11.3%	15.3%	16.1%	17.0%	9.3%	13.2%	14.2%	15.2%	-2.3x	1.2x	0.7x	0.2×
INVISIO AB	1,725	45.9%	23.9%	16.9%	14.9%	25.6%	30.0%	30.6%	29.3%	21.1%	25.8%	27.0%	28.3%	21.1%	25.8%	27.0%	28.3%	-0.5×	-0.8×	-1.1x	0.3×
Saab AB Class B	17,838	23.5%	14.0%	15.1%	15.0%	13.2%	13.4%	13.6%	14.1%	9.0%	9.4%	9.8%	10.3%	9.0%	9.4%	9.8%	10.3%	-0.2x	0.0x	-0.1x	0.1×
Kongsberg Gruppen ASA	24,294	20.3%	17.5%	15.3%	12.5%	16.5%	16.6%	16.9%	17.3%	14.2%	14.6%	15.3%	15.3%	13.4%	13.8%	14.4%	14.9%	-l.lx	-0.8×	-0.9x	-I.Ix
Average	5,638	27.1%	30.0%	16.8%	14.1%	13.7%	17.6%	19.3%	20.7%	6.1%	10.6%	12.9%	15.0%	6.0%	10.2%	12.5%	14.7%	0.8x	0.2x	-0.1x	0.0x
Median	535	19.9%	17.6%	15.2%	13.2%	12.6%	16.6%	17.2%	17.9%	7.9%	9.4%	10.9%	14.3%	7.3%	9.4%	10.9%	14.1%	-0.3x	0.0x	-0.1x	0.1x
European defence companies																					
Chemring Group PLC	1,366	8.0%	6.0%	11.6%	13.5%	16.9%	17.5%	18.0%	18.8%	13.9%	14.0%	14.5%	15.8%	14.0%	14.0%	14.4%	15.7%	0.7×	1.0x	0.9x	0.5×
QinetiQ Group plc	3,276	6.7%	7.3%	7.0%	8.7%	14.7%	15.1%	15.2%	-	12.6%	12.8%	12.9%	11.7%	11.5%	11.9%	12.0%	11.7%	0.3×	0.0x	-0.4×	-
RENK Group AG	3,738	21.5%	15.4%	14.7%	13.7%	19.7%	20.4%	21.0%	21.6%	14.9%	16.6%	17.2%	19.0%	15.3%	16.6%	17.3%	18.3%	1.8x	1.2x	0.8x	0.4x
Babcock International Group PLC	4,408	10.3%	4.1%	4.2%	2.4%	9.3%	9.8%	10.1%	-	7.1%	7.5%	7.9%	8.4%	7.1%	7.5%	7.8%	8.2%	0.8x	0.6x	0.2x	
HENSOLDT AG	8,062	21.3%	16.6%	12.2%	10.8%	18.1%	18.2%	18.9%	19.9%	13.3%	13.9%	15.3%	15.3%	12.0%	13.0%	13.9%	15.1%	1.7x	1.3x	0.9x	0.6×
Dassault Aviation SA	22,557	29.8%	15.4%	22.7%	12.9%	11.2%	11.9%	12.5%	12.7%	8.3%	8.3%	9.3%	9.9%	7.9%	9.3%	10.0%	9.8%	-8.4×	-8.5×	-6.2×	-3.8x
Leonardo SpA	26,138	16.2%	4.1%	5.5%	6.0%	11.6%	12.3%	12.8%	12.4%	8.4%	8.9%	9.8%	10.3%	7.5%	8.6%	9.2%	9.8%	0.9x	0.6x	0.3×	0.1×
Thales SA	50,538	11.7%	5.1%	6.2%	6.1%	15.8%	16.0%	16.2%	16.2%	11.6%	12.4%	12.9%	13.3%	11.6%	12.4%	12.8%	13.2%	0.8x	0.6x	0.2x	-0.2x
Rheinmetall AG	53,270	39.2%	26.6%	29.4%	25.3%	17.9%	19.2%	20.0%	20.4%	15.3%	16.9%	17.9%	17.7%	14.3%	15.8%	17.2%	18.4%	0.5×	0.4x	0.1×	-0.2x
BAE Systems plc	58.268	4.1%	16.8%	6.5%	5.9%	14.1%	13.5%	13.5%	13.6%	11.4%	10.9%	11.0%	11.2%	11.5%	10.9%	11.0%	11.2%	1.6x	1.3x	l.lx	0.8x
Safran SA	110.441	17.8%	13.9%	11.4%	7.7%	19.8%	20.0%	20.5%	20.6%	15.2%	15.5%	15.8%	16.4%	15.1%	15.9%	16.5%	16.8%	-0.3x	-0.3x	-0.5×	-0.4x
Average	31,096	16.9%	11.9%	12.0%	10.3%	15.4%	15.8%	16.2%	17.4%	12.0%	12.5%	13.1%	13.5%	11.6%	12.3%	12.9%	13.5%	0.0x	-0.2×	-0.2x	-0.2x
Median	22,557	16.2%	13.9%	11.4%	8.7%	15.8%	16.0%	16.2%	18.8%	12.6%	12.8%	12.9%	13.3%	11.6%	12.4%	12.8%	13.2%	0.8x	0.6x	0.2x	0.1×
Europe and Sweden average	20,377	21.2%	19.5%	14.0%	11.9%	14.7%	16.6%	17.5%	18.9%	9.5%	11.7%	13.0%	14.1%	9.2%	11.4%	12.8%	14.0%	0.3x	0.0x	-0.2x	-0.1x
Europe and Sweden median	4,408	17.8%	15.4%	12.4%	12.6%	14.7%	16.6%	16.9%	18.4%	11.4%	12.4%	12.9%	13.3%	11.5%	11.9%	12.0%	13.3%	0.7x	0.6x	0.2x	0.1x
	,																				
American defence companies																					
Huntington Ingalls Industries, Inc.	7,056	0.7%	3.6%	4.1%	4.2%	7.5%	7.9%	8.5%	8.9%					4.6%	5.3%	5.8%	6.2%	2.7×	2.4x	2.1×	1.9x
Curtiss-Wright Corporation	11.331	9.7%	7.9%	6.1%	5.8%	20.9%	21.5%	21.9%	22.2%					17.5%	18.1%	18.5%	19.1%	1.0x	0.2x	-0.3×	-0.5x
Booz Allen Hamilton Holding Corporation Class A	12,935	12.9%	7.5%	7.3%		11.0%	11.1%	11.3%	-					11.2%	9.9%	10.1%	-	2.2×	2.0×	1.8x	
Leidos Holdings, Inc.	16,294	7.9%	3.0%	4.1%	2.6%	12.9%	12.8%	12.8%	13.0%					12.0%	11.9%	12.0%	12.1%	1.7x	1.6x	1.5×	1.4x
L3Harris Technologies Inc	36,832	9.8%	3.7%	4.1%	3.9%	18.6%	18.2%	18.6%	18.4%					15.4%	15.7%	16.2%	13.8%	2.9x	2.6×	2.3×	2.1x
Northrop Grumman Corp.	63,771	4.4%	3.3%	4.4%	4.5%	14.0%	14.8%	14.3%	13.9%					10.6%	11.4%	10.9%	11.0%	1.9x	1.7x	1.7x	1.7x
General Dynamics Corporation	66,046	12.9%	5.4%	4.4%	2.8%	11.9%	12.1%	12.6%	12.9%					10.1%	10.3%	10.9%	11.2%	1.2x	1.1x	1.0x	0.9×
Lockheed Martin Corporation	100,684	5.1%	4.7%	3.9%	3.4%	12.1%	14.2%	14.2%	14.2%					9.9%	12.1%	12.2%	12.2%	2.1x	1.6x	1.5×	1.5×
Honeywell International Inc.	126,342	5.0%	5.3%	4.9%	4.7%	24.4%	26.3%	26.9%	26.4%		24.4%	25.0%	24.9%	22.6%	23.4%	24.1%	24.2%	2.1x	1.7x	1.4x	1.5×
RTX Corporation	160,439	8.7%	4.2%	5.8%	5.7%	16.0%	16.8%	17.1%	17.2%	12.6%	13.0%	13.9%	14.7%	12.6%	13.1%	13.7%	14.1%	2.8×	2.3×	1.9x	1.8x
Average	60,173	7.7%	4.9%	4.9%	4.2%	14.9%	15.6%	15.8%	16.3%	12.6%	18.7%	19.5%	19.8%	12.7%	13.1%	13.4%	13.8%	2.1x	1.7x	1.5x	1.3x
Median	50,301	8.3%	4.5%	4.4%	4.2%	13.5%	14.5%	14.2%	14.2%	12.6%	18.7%	19.5%	19.8%	11.6%	12.0%	12.1%	12.2%	2.1x	1.7x	1.6x	1.5x
		13.8%	14.5%	14.5%	16.3%	15.6%	15.6%	15.3%	15.0%	11.8%	12.6%	12.9%	13.2%	11.8%	10.7%	5.8%	-0.6%	0.3x	0.2x	0.3x	0.3x
Total average	16,761																				

\*Carnegie Estimates

Note: Estimates collected from Factset as per 06/03/202

EV/EBITA !Se 2026e 2027e 2027e 2027e 2027e 2027e Swedish defence co KebNi AB Class B\* 12.9x 7.9x 5.9x 14.4x 15.9x 23.4x 14.3x 21.4x 14.5x 14.4x 41.6x 152.5x 19.3x 1693.5x 29.0x 37.5x 27.9x 18.8x 30.7x 12.8x 36.6x 27.4x 33.5x 25.5x 31.8x 27.1x 29.1x 35 91 53 126 943 1,725 17,838 24,294 5,638 2.0x 2.5x 1.5x 2.0x 2.9x 7.2x 2.1x 3.7x 3.0x 2.3x 28.1× 29.6× 13.7× 51.2× 24.4× 31.6× 23.0× 28.9× 28.8× 28.5× 3.8x 2.8x 1.2x 3.3x 8.7x 7.2x 2.0x 4.4x 4.2x 3.5x 24.7x 19.8x 19.4x 35.6x 27.2x 15.5x 30.9x 19.2x 18.3x 53.5x 52.0x 42.8x 35.6x European defence or Chemring Group PLC QinetiQ Group plc RENK Group AG Babcock International O HENSOLDT AG Dassault Aviation SA Leonardo SpA Thales SA Rheinmetall AG 1,366 3,276 3,738 4,408 8,062 22,557 26,138 50,538 53,270 58,268 110,441 31,096 2.3x 1.5x 3.3x 0.8x 3.6x 2.1x 1.7x 2.5x 4.3x 1.8x 3.4x 11.4x 10.9x 13.3x 9.4x 19.0x 15.4x 14.5x 16.7x 14.8x 14.7x 17.3x 21.2x 15.1x 27.8x 15.0x 39.5x 21.1x 26.0x 26.0x 40.0x 21.5x 31.9x 2.0x 1.4x 2.9x 0.8x 3.2x 1.7x 1.6x 2.4x 3.3x 1.7x 3.1x 1.8x 1.3x 2.5x 0.8x 2.9x 1.5x 1.5x 2.2x 2.6x 1.6x 2.8x 12.9x 9.8x 16.1x 8.6x 19.9x 17.6x 13.6x 15.6x 22.1x 13.7x 17.0x 14.0x 10.8x 16.6x 10.2x 21.1x 18.4x 16.2x 18.3x 18.4x 15.8x 19.3x 14.6x 13.9x 13.3x 12.3x 18.6x 14.8x 14.4x 13.2x 19.8x 13.9x 21.0x 14.1x 11.5x 16.6x 10.3x 23.3x 17.1x 17.2x 18.3x 19.1x 15.7x 18.5x 11.4x 10.9x 13.8x 9.6x 19.2x 15.4x 15.2x 16.8x 14.7x 16.8x 18.5x 13.6x 22.8x 13.6x 32.7x 17.5x 22.0x 23.1x 28.1x 19.4x 25.7x 21.6x 1.6x 2.0x 0.9x 2.2x 1.2x 1.1x 1.5x 2.8x 1.6x 3.2x 9.1x 13.6x 8.0x 17.1x 13.8x 12.4x 14.5x 16.4x 12.8x 14.9x 12.7x 13.7x 12.3x 16.9x 14.1x 12.9x 13.2x 18.5x 13.9x 11.6x 19.8x 11.2x 26.0x 25.4x 18.8x 20.2x 25.2x 17.0x 22.0x 12.5x 19.8x 11.2x 27.9x 22.6x 19.4x 20.2x 26.9x 16.9x 21.5x 17.0x 37.0x 16.7x 46.5x 22.0x 29.1x 35.9x 56.2x 23.8x 35.5x 12.3x 18.9x 12.1x 26.5x 15.2x 20.3x 21.1x 21.0x 17.8x 22.9x 10.9x 10.4x 9.4x 12.4x 10.4x 9.4x 9.7x 15.9x 11.3x 16.0x 11.7x 14.6x 12.0x 12.1x 13.7x 12.8x 12.0x 13.7x 12.5x 12.1x 13.4x 12.9x 20.9x 10.9x 21.7x 17.1x 12.4x 17.0x 14.8x 21.0x 7,056 11,331 12,935 16,294 36,832 63,771 66,046 100,684 126,342 10.9x 17.9x 11.8x 10.2x 13.2x 13.4x 13.5x 12.2x 15.0x 8.9x 15.5x 18.8x 26.5x 12.6x 11.7x 15.9x 19.0x 17.1x 19.3x 19.5x 14.1x 19.6x 12.1x 10.5x 14.2x 17.3x 14.4x 13.7x 15.6x 12.6x 18.0x 11.7x 23.7x 13.7x 11.3x 16.0x 16.4x 15.7x 15.5x 18.3x 10.2x 21.5x 0.8x 3.4x . 1.2x 2.2x 1.8x 1.5x 1.6x 3.6x 10.5x 15.1x 15.2x 14.5x 14.5x 16.8x 9.4x 12.0x 13.0x 11.8x 11.4x 13.6x 17.0x 13.9× 15.4x 14.9x 17.4x 2.4x 2.3x 15.0x 13.3x 19.1x 18.0x 13.1x 14.9x 14.5x 19.3x 14.4x 19.1x 15.3x 15.8x 15.1x 19.8x 18.3x 2.0x 2.6x 2.0x 14.9x 16.2x 15.4x 1.8x 2.5x 1.8x 2.3x 2.1x

\*Carnegie Estimates Note: Estimates collected from Factset as per 06/03/2025



## Valuation and different scenarios of Roda acquisition

Based on the benchmarking against both European defence peers and the broader peer group of companies with similar valuations listed on the OMXS All-Share, we believe an EV/EBITA multiple of 18.2–22.2x is appropriate at this time. Applying this to our 2026e EBITA estimates results in a fair equity value range of SEK195–240 per share.

To highlight the potential risks in our estimates and their impact on the fair value range, we have developed three scenarios in which we adjust Roda's financials while keeping MilDef's organic estimates intact. It is important to note that while Roda is showing lower sales and margins than initially estimated, this does not necessitate adjustments to our other scenarios. The recent positive shift in communication from the German government makes us believe that historical performance is less relevant for predicting future outcomes. The first scenario represents our base case, which is the one we have used to evaluate MilDef.


The second scenario assumes that Roda's sales growth falls short of our expectations and that this trend will continue. In this case, we expect margins to erode, as we believe MilDef would incur additional costs to achieve growth. Using the same multiples, we reach a fair value range of SEK163–201 per share.

In the third scenario, where we have underestimated Roda's growth both in 2024 and in the future, we expect margins to scale accordingly. Our research on Swedish distributors reveals that opexto-sales ratios in several cases are below 10%. Given this, we see the potential for Roda to achieve EBITA margins of 18–19%, especially if the group is able to negotiate better prices with its suppliers. In this scenario, we reach a fair value range of SEK218–268 per share.

Roda scenario b	ased on o	ur estimate	es			Group estin	nate			Equity value per sh	are based on 2026e
SEKm	2023	2024e	2025e	2026e	2027e	2024	2025e	2026e	2027e	EV/EBITA(26e) low	EV/EBITA(26e) high
Sales	823	1,006	1,177	1,353	1,556	1,201	2,578	3,234	3,670		
Sales growth		22%	17%	15%	15%	4%	115%	25%	13%	18.2x	22.2x
COGS	-584	-704	-824	-947	-1,089	-612	-1,497	-1,900	-2,143	195	240
Gross profit	239	302	353	406	467	589	1,081	1,333	1,528	1	'
Gross margin	29%	30%	30%	30%	30%	49.0%	41.9%	41.2%	41.6%		
EBITA	130	161	191	230	271	136	394	526	624		
EBITA marign	15.8%	16.0%	16.2%	17.0%	17.4%	11.3%	15.3%	16.3%	17.0%		
										Source: Car	negie Research, MilDef
Roda low growt	h scenario					Group low g	growth sce	nario		Equity value per sh	are based on 2026e
SEKm	2023	2024e	2025e	2026e	2027e	2024	2025e	2026e	2027e	EV/EBITA(26e) low	EV/EBITA(26e) high
Sales	823	905	978	1,056	1,140	1,201	2,412	2,936	3,254		
Sales growth		10%	8%	8%	8%	4%	101%	22%	11%	18.2x	22.2x
COGS	-584	-634	-684	-739	-798	-612	-1,381	-1,692	-1,852	163	201
Gross profit	239	272	293	317	342	589	1,031	1,244	1,403		
Gross margin	29%	30%	30%	30%	30%	49.0%	42.8%	42.4%	43.1%		
EBITA	130	136	137	148	160	136	348	444	513		
EBITA marign	15.8%	15.0%	14.0%	14.0%	14.0%	11.3%	14.4%	15.1%	15.8%		
						S	ource: Carn	egie Researd	h, MilDef	Source: Car	negie Research, MilDef
Roda high grow	th scenario	•				Group high	growth sce	nario		Equity value per sh	are based on 2026e
SEKm	2023	2024e	2025e	2026e	2027e	2024	2025e	2026e	2027e	EV/EBITA(26e) low	EV/EBITA(26e) high
Sales	823	1,070	1,337	1,605	1,878	1,201	2,712	3,485	3,992		
Sales growth		30%	25%	20%	17%	4%	126%	29%	15%	18.2x	22.2x
COGS	-584	-749	-936	-1,123	-1,314	-612	-1,590	-2,077	-2,368	218	268
Gross profit	239	321	401	481	563	589	1,121	1,409	1,624		
Gross margin	29%	30%	30%	30%	30%	49.0%	43.5%	43.6%	44.3%		
EBITA	130	171	227	289	357	136	424	585	710		







Source: Carnegie Research

Average year

Terminal

#### **DCF**

While our fair value range is primarily based on the scenario and benchmarking analysis detailed above, we have also conducted a DCF valuation. Following our explicit forecast period, which ends in 2026e, we assume growth will gradually decline linearly to 2%, in line with long-term GDP growth. We apply a WACC of 9.0%, reflecting an equity beta of 1.4x, and use the net debt for 2025e to reflect the increased debt due to the acquisition of Roda. For the terminal period, we use a 2% growth rate and assume an EBIT margin of 15%. Our DCF analysis suggests a fair value of SEK182 per share.

DCF assumptions - Summary	2025e	2026e	2027e	4-5	6-10	11-15	16-20	period
Total sales growth	114.7%	25.4%	13.5%	13.9%	11.2%	7.4%	3.5%	2.0%
EBITDA margin	16.6%	17.6%	18.4%	18.5%	18.6%	18.8%	18.9%	19.0%
Depreciation % of sales	-1.6%	-1.4%	-1.4%	-1.5%	-1.6%	-1.8%	-1.9%	-2.0%
EBITA margin	15.1%	16.2%	17.0%	17.0%	17.0%	17.0%	17.0%	17.0%
Amortisations % of sales	-2.1%	-1.9%	-1.8%	-1.8%	-1.8%	-1.9%	-2.0%	-2.0%
EBIT margin	13.0%	14.3%	15.2%	15.2%	15.2%	15.1%	15.0%	15.0%
Capex % of sales	-1.9%	-1.8%	-1.5%	-1.7%	-2.2%	-3.0%	-3.7%	-4.0%
Paid tax rate	-26.0%	-26.0%	-26.0%	-26.0%	-26.0%	-26.0%	-26.0%	-26.0%
NWC to sales	38.5%	38.8%	35.2%	35.5%	36.0%	36.9%	37.7%	38.0%
Sales	2,578	3,234	3,670	4,475	6,697	10,183	12,979	13,966
EBITDA	429	569	677	827	1,246	1,912	2,458	2,654
Capex	-49	-58	-55	-77	-152	-304	-482	-279
Taxes	-80	-112	-138	-198	-296	-450	-574	617
Other	-1,112	-211	10	-199	-249	-269	-184	19,811
Free cash flow	-812	187	494	353	549	888	1,218	22,802
Discounted FCF	-778	165	399	250	285	301	270	4,268
Share of total discounted FCF	-9%	2%	5%	6%	16%	17%	15%	48%
Valuation	(SEK)m	Per share		v	VACC assur	mptions		
EV (discounted FCF)	8,837	188.2			isk free intere	•		4.0%
- Net debt (2026)	-417	-8.9			ebt risk prem	nium		0.5%
+ Associates	0	0.0			quity risk pre			4.0%
- Minority interest	0	0.0			quity beta			1.40
- Outstanding warrants	0	0.0			ost of Equit	: <b>y</b>		9.6%
Other debt adjustments	0	0.0			ax rate	•		26.0%
ESG penalty	0	0.0		Α	fter tax cost	of debt		3.3%
Equity value at YE (24)	8,421	179		E	quity weight			90%
Time adjustment	141	3.0			VACC			9.0%
Dividend	0	0.0						
Current equity value	8,56 I	182						

Source: Carnegie Research



The DCF valuation is highly sensitive to the applied WACC and terminal growth and margin assumptions, as reflected below.

					WACC			
		7.5%	8.0%	8.5%	9.0%	9.5%	10.0%	10.5%
%	4%	338	288	249	217	192	170	152
	3%	307	265	232	204	181	161	145
growth	3%	283	247	217	192	172	154	139
	2%	263	231	205	182	163	147	133
Terminal	2%	246	218	194	174	156	141	128
Ē	1%	232	206	185	166	150	136	124
ř	1%	219	196	176	159	144	131	120

					WACC			
		7.5%	8.0%	8.5%	9.0%	9.5%	10.0%	10.5%
%	22%	294	258	227	202	180	161	145
Δ	21%	284	249	220	195	174	157	141
EBITI	20%	273	240	212	189	169	152	137
	19%	263	231	205	182	163	147	133
rminal	18%	252	222	197	176	158	142	129
E	17%	242	213	190	170	152	138	125
Pe P	16%	231	204	182	163	147	133	121

Source: Carnegie Research

Source: Carnegie Research

		fi		

MilDef				0										
P&L (SEKm)	Q1(24)	Q2(24)	Q3(24)	Q4(24)	Q1(25e)	Q2(25e)	Q3(25e)	Q4(25e)	2022	2023	2024	2025e	2026e	2027e
Net sales	232	302	250	418	434	697	585	862	739	1,151	1,201	2,578	3,234	3,670
Growth Y/Y	-18%	4%	10%	18%	87%	131%	134%	106%	57%	56%	4%	115%	25%	13%
Organic Y/Y	-18%	4%	10%	18%	45%	30%	35%	27%	27%	40%	4%	33%	17%	13%
Acquired Y/Y	0%	0%	0%	0%	42%	101%	99%	79%	30%	16%	0%	82%	9%	0%
COGS	-120	-148	-125	-220	-241	-412	-341	-502	-387	-595	-612	-1,497	-1,900	-2,143
Gross profit	112	154	125	198	193	285	243	360	352	556	589	1,081	1,333	1,528
Gross margin	48.4%	51.1%	50.0%	47.4%	44.5%	40.9%	41.6%	41.7%	47.7%	48.3%	49.0%	41.9%	41.2%	41.6%
OPEX	-117	-119	-106	-127	-152	-191	-169	-233	-323	-449	-469	-746	-872	-969
Selling expenses	-71	-70	-61	-76	-89	-117	-104	-152	-206	-283	-279	-462	-537	-614
Admin expenses	-25	-25	-27	-29	-36	-45	-38	-48	-67	-86	-106	-167	-187	-203
R&D	-22	-24	-17	-22	-27	-30	-27	-34	-49	-81	-84	-117	-148	-152
Other income/expenses	-2	-1	3	-314	0	0	0	0	-1	1	-329	0	0	C
EBITDA	9	54	38	-243	60	121	97	150	60	168	143	429	569	677
EBITDA margin	3.7%	17.8%	15.4%	-58.1%	13.9%	17.4%	16.7%	17.4%	8.1%	14.6%	11.9%	16.6%	17.6%	18.4%
Depreciation	-10	-12	-10	-10	-10	-11	-9	-10	-19	-39	-43	-41	-45	-52
Adj. EBITA - CAR definition	-2	42	28	68	51	114	89	141	42	129	136	394	526	624
Adj. EBITA margin - CAR definition	-0.8%	13.9%	11.2%	16.3%	11.6%	16.3%	15.2%	16.4%	5.6%	11.2%	11.3%	15.3%	16.3%	17.0%
Amortisation - PPA	-5	-8	-6	-5	-9	-16	-14	-14	-12	-21	-24	-53	-62	-66
EBIT	-7	34	22	-258	41	94	74	126	29	108	-209	335	461	559
EBIT margin	-3.0%	11.3%	8.7%	-61.8%	9.5%	13.4%	12.7%	14.7%	4.0%	9.4%	-17.4%	13.0%	14.3%	15.2%
Adj. EBIT	-7	34	22	63	41	98	75	127	29	108	112	341	463	559
Adj. EBIT margin	-3.0%	11.3%	8.7%	15.0%	9.5%	14.0%	12.9%	14.8%	4.0%	9.4%	9.3%	13.2%	14.3%	15.2%
Net financials	-3.070	-5	-I	-2	0	-10	-9	-9	-10	-20	-14	-29	-31	-28
PTP	-13	29	21	-260	41	84	65	117	19	88	-223	307	430	530
Tax	2	-6	-4	10	-11	-22	-17	-30	-5	-20	2	-80	-112	-138
Net profit	-12	23	17	-250	30	62	48	86	14	69	-220	227	318	393
EPS	-0.3	0.6	0.4	-5.8	0.7	1.4	1.1	1.9	0.4	1.7	-5.2	4.9	6.8	8.4
Net sales growth Y/Y	-18%	4%	10%	18%	87%	131%	134%	106%	57%	56%	4%	115%	25%	13%
Organic	-18%	4%	10%	18%	45%	30%	35%	27%	27%	40%	4%	33%	17%	13%
Acquired	0%	0%	0%	0%	42%	101%	99%	79%	30%	16%	0%	82%	9%	0%
Gross margin	48.4%	51.1%	50.0%	47.4%	44.5%	40.9%	41.6%	41.7%	47.7%	48.3%	49.0%	41.9%	41.2%	41.6%
EBITDA margin	3.7%	17.8%	15.4%	-58.1%	13.9%	17.4%	16.7%	17.4%	8.1%	14.6%	11.9%	16.6%	17.6%	18.4%
EBITA margin	-0.8%	13.9%	11.2%	7.8%	11.6%	15.8%	15.0%	16.2%	5.6%	11.2%	8.4%	15.1%	16.2%	17.0%
EBIT margin	-3.0%	11.3%	8.7%	-61.8%	9.5%	13.4%	12.7%	14.7%	4.0%	9.4%	-17.4%	13.0%	14.3%	15.2%
Share of sales per region	F30'	F.40′	(20)	4101	F20/	2101	222/	2001	400/	4001	F00'	2701	2201	200
Nordics	53%	54%	62%	61%	53%	31%	32%	38%	62%	60%	58%	37%	33%	32%
Europe (excl. Nordics)	23%	34%	22%	23%	28%	58%	56%	51%	16%	19%	26%	51%	56%	57%
North America	20%	11%	13%	10%	16%	6%	7%	6%	20%	16%	13%	8%	7%	7%
Other	4%	1%	3%	6%	4%	5%	5%	5%	2%	4%	4%	5%	5%	5%
Y/Y growth by region														
Nordics	-18%	-20%	41%	9%	45%	34%	21%	26%	36%	53%	0%	30%	16%	10%
Europe (excl. Nordics)	-27%	181%	-8%	83%	75%	292%	486%	354%	49%	87%	38%	310%	43%	15%
Europe (excl. Nordics) North America	-27% -14%	181% 43%	-8% -34%	83% -31%	75% 17%	292% 22%	486% 22%	354% 32%	49% 196%	87% 23%	38% -18%	310% 23%	43% 13%	15%

Source: Carnegie Research, MilDef ırch, MilDef



## **Financial statements**

Profit & loss (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	0	0	0	470	739	1,151	1,201	2,578	3,234	3,670
COGS	0	0	0	-260	-387	-595	-612	-1, <del>4</del> 97	-1,900	-2,143
Gross profit	0	0	0	210	352	556	589	1,081	1,333	1,528
Other income & costs	0	0	0	-189	-292	-388	-446	-652	-765	-851
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
EBITDA	0	0	0	21	60	168	143	429	569	677
Depreciation PPE	0	0	0	-13	-15	-28	-29	-36	-41	-45
Depreciation lease assets	0	0	0	0	0	0	0	0	0	0
Amortisation development costs	0	0	0	-2	-3	-11	-13	-4	-4	-8
Amortisation other intangibles	0	0	0	0	0	0	0	0	0	0
Impairments / writedowns	0	0	0	0	0	0	0	0	0	0
EBITA	0	0	0	6	41	129	100	388	524	624
Amortization acquisition related	0	0	0	-9	-12	-21	-24	-53	-62	-66
Impairment acquisition related	0	0	0	0	0	0	-285	0	0	0
EBIT	0	0	0	-3	29	108	-209	335	461	559
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
Net financial items	0	0	0	-2	-10	-20	-14	-29	-31	-28
of which interest income/expenses	0	0	0	-2	-10	-20	-14	-29	-31	-28
of which interest on lease liabilities	0	0	0	0	0	0	0	0	0	0
of which other items	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	0	0	0	-5	19	89	-223	307	430	530
Taxes	0	0	0	5	-5	-20	2	-80	-112	-138
Post-tax minorities interest	0	0	0	0	0	0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Net profit	0	0	0	-1	14	69	-220	227	318	393
Adjusted EBITDA	0	0	0	32	60	168	179	435	571	677
Adjusted EBITA	0	0	0	18	42	129	136	394	526	624
Adjusted EBIT	0	0	0	9	29	108	112	341	463	559
Adjusted net profit	0	0	0	17	27	90	54	284	382	458
Sales growth Y/Y	na	na	na	+chg	57.3%	55.8%	4.3%	114.7%	25. <del>4</del> %	13.5%
EBITDA growth Y/Y	na	na	na	+chg	188.5%	180.0%	-14.8%	199.6%	32.6%	19.0%
EBITA growth Y/Y	na	na	na	+chg	558.8%	211.0%	-22.3%	287.2%	34.9%	19.2%
EBIT growth Y/Y	na	na	na	-chg	+chg	270.2%	-chg	+chg	37.6%	21.1%
EBITDA margin	nm	nm	nm	4.4%	8.1%	14.6%	11.9%	16.6%	17.6%	18.4%
EBITA margin	nm	nm	nm	1.3%	5.6%	11.2%	8.4%	15.1%	16.2%	17.0%
EBIT margin	nm	nm	nm	-0.6%	4.0%	9.4%	-17.4%	13.0%	14.3%	15.2%
Tax rate	na	na	na	84.9%	26.0%	22.1%	1.0%	26.0%	26.0%	26.0%
Cash flow (SEKm)	2018	2019	2020		2022	2023	2024	2025		2027
			2020	2021	2022		4044	2025e	2026e	2027e
FRITDA	0			2021				2025e	2026e	2027e
EBITDA Paid taxes	0	0	0	21	60	168	143	429	569	677
Paid taxes	0	0	0	21 -8	60 -8	168 -13	143 -22	429 -80	569 -112	677 -138
Paid taxes Change in NWC	0	0 0 0	0 0 0	21 -8 -66	60 -8 -123	168 -13 -90	143 -22 8	429 -80 -258	569 -112 -211	677 -138 10
Paid taxes Change in NWC Non cash adjustments	0 0 0	0 0 0 0	0 0 0 0	21 -8 -66 -1	60 -8 -123 -1	168 -13 -90 9	143 -22 8 77	429 -80 -258 0	569 -112 -211 0	677 -138 10 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations	0 0 0	0 0 0 0	0 0 0 0	21 -8 -66 -1 0	60 -8 -123 -1 0	168 -13 -90 9 0	143 -22 8 77 0	429 -80 -258 0	569 -112 -211 0	677 -138 10 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities	0 0 0 0 <b>0</b>	0 0 0 0 0	0 0 0 0 0	21 -8 -66 -1 0	60 -8 -123 -1 0	168 -13 -90 9 0 <b>74</b>	143 -22 8 77 0 <b>206</b>	429 -80 -258 0 0	569 -112 -211 0 0 246	677 -138 10 0 0 549
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets	0 0 0 0 <b>0</b>	0 0 0 0 0 0	0 0 0 0 0 0	21 -8 -66 -1 0 -55	60 -8 -123 -1 0 - <b>72</b> -5	168 -13 -90 9 0 <b>74</b> -14	143 -22 8 77 0 <b>206</b> -11	429 -80 -258 0 0 92	569 -112 -211 0 0 246 -32	677 -138 10 0 0 <b>549</b> -26
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs	0 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11	60 -8 -123 -1 0 - <b>72</b> -5 -13	168 -13 -90 9 0 <b>74</b> -14	143 -22 8 77 0 <b>206</b> -11	429 -80 -258 0 0 92 -26	569 -112 -211 0 0 246 -32 -26	677 -138 10 0 0 549 -26 -29
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets	0 0 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6	60 -8 -123 -1 0 -72 -5 -13	168 -13 -90 9 0 <b>74</b> -14 -32	143 -22 8 77 0 <b>206</b> -11 -10	429 -80 -258 0 0 <b>92</b> -26 -24	569 -112 -211 0 0 <b>246</b> -32 -26 0	677 -138 10 0 0 <b>549</b> -26 -29
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments	0 0 0 <b>0</b> 0 0	0 0 0 0 0 0	0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0	60 -8 -123 -1 0 -72 -5 -13 0	168 -13 -90 9 0 <b>74</b> -14 -32 0	143 -22 8 77 0 206 -11 -10 0	429 -80 -258 0 0 92 -26 -24 0 -854	569 -112 -211 0 0 <b>246</b> -32 -26 0 0	677 -138 10 0 0 549 -26 -29 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments	0 0 0 0 0 0 0	0 0 0 0 0 0	0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172	60 -8 -123 -1 0 -72 -5 -13 0 -383	168 -13 -90 9 0 <b>74</b> -14 -32 0 -23	143 -22 8 77 0 206 -11 -10 0 -13	429 -80 -258 0 0 <b>92</b> -26 -24 0 -854	569 -112 -211 0 0 246 -32 -26 0 0	-138 10 0 0 549 -26 -29 0 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0	60 -8 -123 -1 0 -72 -5 -13 0 -383 0	168 -13 -90 9 0 <b>74</b> -14 -32 0 -23 0	143 -22 8 77 0 206 -11 -10 0 -13 0	429 -80 -258 0 0 92 -26 -24 0 -854 0	569 -112 -211 0 0 246 -32 -26 0 0 0 -58	677 -138 10 0 0 549 -26 -29 0 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401	168 -13 -90 9 0 <b>74</b> -14 -32 0 -23 0 <b>-69</b>	143 -22 8 77 0 206 -11 -10 0 -13 0 -33	429 -80 -258 0 0 <b>92</b> -26 -24 0 -854 0 <b>-903</b>	569 -112 -211 0 0 246 -32 -26 0 0 0 -58	-138 -138 -10 0 0 549 -26 -29 0 0 0 -55
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10	168 -13 -90 9 0 <b>74</b> -14 -32 0 -23 0 <b>-69</b> -20 -21	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22	429 -80 -258 0 0 <b>92</b> -26 -24 0 -854 0 <b>-903</b>	569 -112 -211 0 0 246 -32 -26 0 0 -58 -31	677 -138 10 0 0 549 -26 -29 0 0 0 -55 -28
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 -21 0	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20	429 -80 -258 0 0 <b>92</b> -26 -24 0 -854 0 <b>-903</b> -29 -22	569 -112 -211 0 0 246 -32 -26 0 0 -58 -31 -22 -45	677 -138 10 0 549 -26 -29 0 0 -55 -28 -22 -61
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 -223	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 -21 0	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23	569 -112 -211 0 0 246 -32 -26 0 0 0 -58 -31 -22 -45 0	677 -138 10 0 0 549 -26 -29 0 0 -55 -28 -22 -61 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks Change in bank debt	0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392 0	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 223 180	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 0 60	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495 -118	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23 0 320	569 -112 -211 0 0 246 -32 -26 0 0 -58 -31 -22 -45	677 -138 10 0 0 549 -26 -29 0 0 -55 -28 -22 -61 0 -80
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks	0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 -223	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 -21 0	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23	569 -112 -211 0 0 246 -32 -26 0 0 -58 -31 -22 -45 0 -80	677 -138 10 0 0 549 -26 -29 0 0 -55 -28 -22 -61 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks Change in bank debt Other cash flow items	0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392 0	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 223 180 5	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 -21 0 60 0	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495 -118 0	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23 0 320 0	569 -112 -211 0 0 246 -32 -26 0 0 -58 -31 -22 -45 0 -80 0	677 -138 10 0 0 549 -26 -29 0 0 -55 -28 -22 -61 0 -80 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks Change in bank debt Other cash flow items Total financing activities	0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392 0 0 363	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 223 180 5	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 0 60 0 19	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495 -118 0 322	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23 0 320 0 246	569 -112 -211 0 0 246 -32 -26 0 0 -58 -31 -22 -45 0 -80 0 -179	677 -138 10 0 0 549 -26 -29 0 0 -55 -28 -22 -61 0 -80 0
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks Change in bank debt Other cash flow items Total financing activities Operating cash flow Free cash flow Net cash flow Net cash flow	0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392 0 0 363 -55 -82 120	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 223 180 5 361 -72 -111 -113	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 -21 0 0 60 0 19 74 -13 24	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495 -118 0 322 206 150 495	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23 0 320 0 246 92 -9 -565	569 -112 -211 0 0 246 -32 -26 0 0 0 -58 -31 -22 -45 0 -80 0 -179 246 134	677 -138 10 0 0 549 -26 -29 0 0 0 -55 -28 -22 -61 0 -80 0 -191 549 444 303
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks Change in bank debt Other cash flow items Total financing activities Operating cash flow Free cash flow	0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392 0 0 363 -55 -82	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 223 180 5 361 -72 -111	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 -21 0 0 60 0 19	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495 -118 0 322 206 150	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23 0 320 0 246 92 -9	569 -112 -211 0 0 246 -32 -26 0 0 -58 -31 -22 -45 0 -80 0 -179 246 134	677 -138 10 0 549 -26 -29 0 0 -55 -28 -22 -61 0 -80 0 -191 549
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks Change in bank debt Other cash flow items Total financing activities Operating cash flow Free cash flow Net cash flow Net cash flow	0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392 0 0 363 -55 -82 120	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 223 180 5 361 -72 -111 -113	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 -21 0 0 60 0 19 74 -13 24	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495 -118 0 322 206 150 495	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23 0 320 0 246 92 -9 -565	569 -112 -211 0 0 246 -32 -26 0 0 0 -58 -31 -22 -45 0 -80 0 -179 246 134	677 -138 10 0 0 549 -26 -29 0 0 0 -55 -28 -22 -61 0 -80 0 -191 549 444 303
Paid taxes Change in NWC Non cash adjustments Discontinued operations Total operating activities Capex tangible assets Capitalised development costs Capex - other intangible assets Acquisitions/divestments Other non-cash adjustments Total investing activities Net financial items Lease payments Dividend paid and received Share issues & buybacks Change in bank debt Other cash flow items Total financing activities Operating cash flow Free cash flow Net cash flow Change in net IB debt	0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0	21 -8 -66 -1 0 -55 -11 -6 0 -172 0 -188 -2 -9 -17 392 0 0 363 -55 -82 120 132	60 -8 -123 -1 0 -72 -5 -13 0 -383 0 -401 -10 -11 -27 223 180 5 361 -72 -111 -113 -279	168 -13 -90 9 0 74 -14 -32 0 -23 0 -69 -20 -21 0 0 60 0 19 74 -13 24 -17	143 -22 8 77 0 206 -11 -10 0 -13 0 -33 -14 -22 -20 495 -118 0 322 206 150 495 637	429 -80 -258 0 0 92 -26 -24 0 -854 0 -903 -29 -22 -23 0 320 0 246 92 -9 -565 -863	569 -112 -211 0 0 246 -32 -26 0 0 0 -58 -31 -22 -45 0 -80 0 -179 246 134 9 111	677 -138 10 0 549 -26 -29 0 0 -55 -28 -22 -61 0 -80 0 -191 549 444 303 405

Source: Carnegie Research & company data



## Financial statements, cont.

Balance sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	<b>2027</b> e
Acquired intangible assets	0	0	0	285	599	576	379	1,097	1,034	968
Other fixed intangible assets	0	0	0	1	0	0	0	0	0	0
Capitalised development	0	0	0	- 11	56	69	13	32	54	75
Tangible assets	0	0	0	15	17	22	20	35	<del>4</del> 7	41
Lease assets	0	0	0	60	85	101	70	45	25	12
Other IB assets (I)	0	0	0	0	0	0	0	0	0	0
Other non-IB assets	0	0	0	6	15	_10	20	20	20	20
Fixed assets	0	0	0	377	772	777	502	1,228	1,179	1,116
Inventories (2)	0	0	0	86	237	290	234	516	744	771
Receivables (2)	0	0	0	136	255	285	330	629	75 I	777
Prepaid exp. & other NWC items (2)	0	0 0	0	41 0	70 0	93 0	87	87 0	87 0	87 0
IB current assets (1) Other current assets	0	0	0	0	0	0	0	0	0	0
Cash & cash equivalents (1)	0	0	0	169	60	82	530	-35	-26	277
Current assets	Ŏ	ŏ	0	432	622	749	1,182	1,197	1,556	1,912
Total assets	ŏ	ŏ	Ŏ	808	1,394	1,526	1,684	2,425	2,735	3,028
					•		-			
Shareholders' equity	0	0	0	568	788	845	1,102	1,306	1,579	1,910
Minorities	0	0 0	0	0	0	0	0	0	0	0
Other equity	0 <b>0</b>	0	<b>0</b>		<b>788</b>					0
<b>Total equity</b> Deferred tax	0	0	0	<b>568</b> 24	35	<b>845</b> 33	1,102 25	1,306 25	1 <b>,579</b> 25	1,910 25
LT IB debt (I)	0	0	0	32	175	133	103	423	343	263
Other IB provisions (I)	0	Ö	0	0	0	0	0	0	0	0
Lease libilities	0	0	0	52	71	76	61	39	17	-5
Other non-IB liabilities	Ô	Ö	Ŏ	0	0	0	0	0	0	0
LT liabilities	Ŏ	Ŏ	ŏ	107	281	242	188	486	384	282
ST IB debt (I)	0	0	0	10	53	131	31	31	31	31
Payables (2)	0	0	0	40	105	114	86	239	327	343
Accrued exp. & other NWC items (2)	0	0	0	0	0	0	0	0	0	0
Other ST non-IB liabilities	0	0	0	84	167	194	277	362	414	461
Liabilities - assets held for sale	0	0	0	0	0	0	0	0	0	0
Current liabilities	0	0	0	133	326	440	394	633	772	836
Total equity and liabilities	0	0	0	808	1,394	1,526	1,684	2,425	2,735	3,028
Net IB debt (=I)	0	0	0	-76	239	259	-336	528	417	12
Net working capital (NWC) (=2)	0	0	0	223	457	553	566	992	1,256	1,293
Capital employed (CE)	0	0	0	680	1,107	1,208	1,302	1,804	1,975	2,205
Capital invested (CI)	0	0	0	583	1,158	1,252	1,036	2,169	2,361	2,314
Equity / Total assets	nm	nm	nm	70%	57%	55%	65%	54%	58%	63%
Net IB debt / EBITDA	nm	nm	nm	-3.6	4.0	1.5	-2.3	1.2	0.7	0.0
Per share data (SEK)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Per share data (SEK)										
Adj. no. of shares in issue YE (m)	0.00	0.00	23.24	36.39	39.86	39.86	45.57	46.95	46.95	46.95
Diluted no. of Shares YE (m)	0.00	0.00	23.24	36.39	39.86	39.86	45.57	46.95	46.95	46.95
EPS	na	na	0.00	-0.03	0.37 0.70	1.73 2.25	-5.16	4.90	6.78 8.14	8.36 9.76
EPS adj. CEPS	na	na	0.00 0.00	0.58 0.47	0.70	2.23	1.27 2.57	6.14 6.45	8.60	10.4
DPS	na 0.00	na 0.00	0.00	0.75	0.75	0.00	0.50	0.50	1.00	1.35
BVPS	na	na	0.00	15.6	19.8	21.2	24.2	27.8	33.6	40.7
Performance measures	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
ROE	nm	nm	nm	-0.3%	2.1%	8.4%	-22.6%	18.8%	22.1%	22.5%
Adj. ROCE pre-tax	na	na	na	na	4.8%	12.0%	11.2%	26.0%	28.4%	30.3%
Adj. ROIC after-tax	na	na	na	na	3.5%	8.3%	11.8%	18.2%	17.2%	19.8%
Valuation	2018	2019	2020	2021	2022	2023	2024	2025e	<b>2026</b> e	2027e
FCF yield	0.0%	0.0%	0.0%	-0.8%	-1.0%	-0.1%	1.4%	-0.1%	1.2%	4.1%
Dividend yield YE	na	na	na	1.4%	0.9%	0.0%	0.4%	0.2%	0.4%	0.6%
Dividend payout ratio	na	na	nm	-2795.0%	201.4%	0.0%	-9.7%	10.2%	14.7%	16.1%
Dividend + buy backs yield YE	na	na	na	1.4%	0.0%	0.8%	0.4%	0.4%	0.6%	0.6%
EV/Sales YE	na	na	na	3.89	4.68	2.50	4.46	4.38	3.45	2.93
EV/EBITDA YE	na	na	na	>50	>50	17.1	37.4	26.3	19.6	15.9
EV/EBITA YE	na	na	na	>50	>50	22.3	>50	29.0	21.3	17.2
						22.3			21.3	
EV/EBITA adj. YE	na	na	na	>50	>50		39.3	28.6		17.2
EV/EBIT YE	na	na	na	neg.	>50	26.6	neg.	33.6	24.2	19.3
P/E YE	na	na	na	nm	>50	38.0	nm	46.7	33.8	27.4
P/E adj. YE	na	na	na	>50	>50	29.1	>50	37.3	28.1	23.5
P/BV YE	na	na	na	3.35	4.09	3.10	5.16	8.23	6.81	5.63
Share price YE (SEK)				52.3	80.8	65.6	125	229		

Source: Carnegie Research & company data



## Disclosures and disclaimers

#### Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries

#### Valuation, methodology, and assumptions

Commissioned research reports include the analyst's assessment of a fair value range over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing

#### Frequency of update

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

#### Analyst certification

The research analyst or analysts responsible for the content of this commissioned research report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this commissioned research report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this commissioned research report.

#### Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this commissioned research report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by information barriers to restrict the flows of sensitive information. Persons outside such barriers may gain access to sensitive information only after having observed applicable procedures. The remuneration of persons involved in preparing this commissioned research report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

## Other material conflicts of interest

This report was commissioned and sponsored by the issuer (issuer-paid research).

#### Distribution restrictions

This commissioned research report is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this commissioned research report does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive it. Investors should seek financial advice regarding the appropriateness of investing in any securities discussed in this commissioned research report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this commissioned research report or its contents. This commissioned research report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to persons that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

This commissioned research report is distributed in Sweden by Carnegie Investment Bank AB. Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland this commissioned research report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finansisia) to Norway this commissioned research report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finansitsynet). In Denmark this commissioned research report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet).

This commissioned research report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie's research analysts located outside of the US are employed by non-US affiliates of Carnegie Inc. ("non-US affiliates") that are not subject to FINRA regulations. Generally, Carnegie research analysts are not registered with or qualified as research analysts with FINRA, and therefore are not subject to FINRA rule 2241 restrictions intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research report. Research reports distributed in the U.S. are intended solely for major US institutional investors and US institutional investors as defined under Rule 15a-6 of the Securities Exchange Act of 1934. This commissioned research report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Reports regarding equity products are prepared by non-US affiliates of and distributed in the United States by Carnegie Inc. under Rule 15a-6(a)(3). When distributed by Carnegie Inc, Carnegie Inc. takes responsibility for the commissioned research report. Any US person who wishes to effect transactions based on this commissioned research report should contact Carnegie Inc. Investors in the US should be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, or be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission. This commissioned research report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie Investment Bank AB. Carnegie UK is authorised and regulated by the Financial Conduct Authority (FCA).

#### Research Disclaimer

This commissioned research report is provided solely for information. It does not constitute or form part of, and shall under no circumstances be considered as an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instrument.

This commissioned research report has been requested and paid for by the issuer and should therefore be considered a marketing communication (i.e. not investment research). Payment for the report has been agreed in advance on a non-recourse basis. As commissioned research, this material can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to a prohibition on dealing ahead of the dissemination of the report.

Carnegie Investment Bank AB is responsible for the preparation of this commissioned research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this commissioned research report in Norway. Carnegie Inc. is responsible for this research report in the US.

The information in this commissioned research report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading. Carnegie gives no representation or warranty, express or implied, about its accuracy or completeness. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this commissioned research report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

#### Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the issuer or an affiliate.

Parts of this commissioned research report may have been submitted to the issuer prior to its publication.

Copyright © 2025 Carnegie



Commissioned Research sponsored by MilDef Group

07 March 2025

## Carnegie Investment Bank AB

Regeringsgatan 56 SE-103 38 Stockholm

Tel +46 8 5886 88 00 Fax +46 8 5886 88 95 www.carnegie.se

A member of the Stockholm Stock Exchange

## Carnegie AS

Fjordalleen 16, 5th Floor PO Box 684, Sentrum NO-0106 Oslo Tel +47 22 00 93 00 Fax +47 22 00 94 00 www.carnegie.no

A member of the Oslo Stock Exchange

## Carnegie Investment Bank, Denmark Branch

Overgaden neden Vandet 9B PO Box 1935 DK-1414 Copenhagen K

Tel +45 32 88 02 00 Fax +45 32 96 10 22 www.carnegie.dk

A member of the Copenhagen Stock Exchange

## Carnegie, Inc.

20 West 55th St. ,
New York N.Y. 10019
Tel +1 212 262 5800 Fax +1 212 265 3946
www.carnegiegroup.com
Member FINRA / SIPC

## Carnegie Investment Bank AB, Finland Branch

Eteläesplanadi 2 PO Box 36 FI-00131 Helsinki

Tel +358 9 618 71 230 Fax +358 9 618 71 720 www.carnegie.fi

A member of the Helsinki Stock Exchange

## Carnegie Investment Bank AB, UK Branch

Finwell House, 26 Finsbury Square London EC2A IDS

Tel +44 20 7216 4000 Fax +44 20 7417 9426 www.carnegie.co.uk

Regulated by the FCA in the conduct of Designated Investment Business in the UK